Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17038523 | 0.90 | CA1 (0.39) | NQO2CA1CA2NAMPTGAA | |
| SCHEMBL17038521 | 0.89 | CA1 (0.39) | NQO2CA1CA2NAMPTGAA | |
| SCHEMBL17038524 | 0.83 | CA1 (0.39) | NQO2CA1CA2NAMPTGAA | |
| SCHEMBL18680095 | 0.81 | CA1 (0.39) | NQO2CA1CA2NAMPTGLA | |
| SCHEMBL18680092 | 0.80 | CA1 (0.38) | NQO2CA1CA2NAMPTGLA | |
| SCHEMBL5142116 | 0.80 | GLA (0.49) | CA1CA2NAMPTGAAGLA | |
| SCHEMBL17038124 | 0.74 | TDP1 (0.43) | CA1CA2KMT2ACA12CA9 | |
| SCHEMBL18680091 | 0.74 | CA1 (0.38) | NQO2CA1CA2NAMPTLMNA | |
| SCHEMBL2843187 | 0.73 | KMT2A (0.57) | GAAKMT2ALMNA | |
| SCHEMBL17038117 | 0.73 | MAPT (0.41) | CA1CA2KMT2ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365210-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | NQO2 1/4885CA1 1613/4885CA2 2563/4885 |
| US-11365210-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | NQO2 1/4885CA1 1613/4885CA2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.